Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:30 AM.
Here’s what investors need to know about the announcement.
Earnings
Intra-Cellular Therapies beat estimated earnings by 23.33%, reporting an EPS of $-0.46 versus an estimate of $-0.6.
Revenue was up $60.31 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.14 which was followed by a 5.68% drop in the share price the next day.
Here’s a look at Intra-Cellular Therapies’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.59 | -0.81 | -0.76 | -0.92 |
| EPS Actual | -0.45 | -0.57 | -0.92 | -0.78 |
| Revenue Estimate | 86.97M | 66.00M | 49.02M | 33.65M |
| Revenue Actual | 87.87M | 71.87M | 55.58M | 35.00M |
To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
